Mineralys Therapeutics, Inc. Common Stock (MLYS)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 76
- Market Cap
- $2.3B
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
SentiSense also tracks daily options readings for Mineralys Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Mineralys Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.